Skip to content

4D Molecular Therapeutics, Inc.

FDMT

CIK 0001650648

← back to feed
Revenue (TTM)
$3.17M
+230,194.6% YoY Q1 Mar 2026
Net Income (TTM)
−$228.27M
+12.9% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$3.86
+18.8% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
-7,829.5%
Q1 Mar 2026
Net Margin
-7,209.9%
Q1 Mar 2026
Free Cash Flow (TTM)
−$181.64M
Q1 Mar 2026
Cash
$72.49M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
49.78M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings